COVID-19 Breakthrough Infections among Patients Aged ≥65 Years in Serbia: Morbidity and Mortality Overview

被引:9
|
作者
Bajci, Monika P. [1 ,2 ]
Lendak, Dajana F. [1 ,3 ]
Ristic, Mioljub [4 ,5 ]
Drljaca, Maja M. [1 ,3 ]
Brkic, Snezana [1 ,3 ]
Turkulov, Vesna [1 ,3 ]
Petrovic, Vladimir [4 ,5 ]
机构
[1] Univ Novi Sad, Fac Med, Dept Infect Dis, Hajduk Veljkova 3, Novi Sad 21112, Serbia
[2] Univ Clin Ctr Vojvodina, COVID Hosp, Miseluk Bb, Petrovaradin 21131, Serbia
[3] Univ Clin Ctr Vojvodina, Clin Infect Dis, Hajduk Veljkova 1, Novi Sad 21112, Serbia
[4] Univ Novi Sad, Fac Med, Dept Epidemiol, Hajduk Veljkova 3, Novi Sad 21112, Serbia
[5] Ctr Dis Control & Prevent, Inst Publ Hlth Vojvodina, Futoska 121, Novi Sad 21000, Serbia
关键词
COVID-19; breakthrough infection; older adults; geriatric medicine; VACCINE; OLD;
D O I
10.3390/vaccines10111818
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BACKGROUND: Vaccines against severe acute respiratory syndrome coronavirus 2 have shown effectiveness in the prevention of COVID-19. Breakthrough infections occur, and age has been shown to be one of the dominant risk factors for poorer outcome. This research focuses on characteristics of breakthrough infections in older adults. METHODS: This retrospective study was conducted for four months (March-June 2021) in the autonomous province of Vojvodina in Serbia on 11,372 patients using reverse-transcription polymerase chain reaction or antigen-detection rapid diagnostic tests verifying COVID-19 in those aged >= 65 years. Demographics, comorbidities, disease severity, and final outcomes were evaluated in fully vaccinated compared to unvaccinated individuals. Individuals were divided into younger-old (65-74 years) and older-old (>= 75 years) age groups and differences between those groups were further evaluated. Binary logistic regression was performed to identify independent predictors of poor outcome. RESULTS: By the end of the research, 51.3% of the population of APV 65-74 years, as well as 46.2% of those older than 74 years, were vaccinated. From the acquired sample, 17.4% had breakthrough infection. Asymptomatic forms were higher in both age groups of vaccinated vs. unvaccinated (3.9%-younger-old, 6.3%-older-old vs. 2.9%-younger-old, 3.9%-older-old). The same results were registered with mild symptoms (82.1%-younger-old, 68.1%-older-old vs. 76.3%-younger-old, 57.5%-older-old) (p < 0.001). The case fatality ratio of the vaccinated population was smaller than the unvaccinated population in both groups (3.1% vs. 7.9%-younger-old; 11.4% vs. 22.5%-older-old) (p < 0.001). The odds ratio for poor outcome in unvaccinated individuals was 2.3 (95% confidence interval, p < 0.001) for the total sample. CONCLUSIONS: An increase in asymptomatic and mild forms, as well as decrease in severe or critical forms and poor outcomes, were noted in the vaccinated population. Choosing to avoid vaccination against SARS-CoV-2 may increase the chance of poor outcome in older individuals.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Impact of vaccination on COVID-19 morbidity and mortality among aged people
    Poli, Priscila
    Ribeiro, Ana Cristina
    Uehara, Silvia Carla da Silva Andre
    REV RENE, 2024, 25
  • [2] COVID-19 related morbidity and mortality among patients with diabetes
    Chaabouni, H.
    Smaoui, F.
    Mnif, K.
    Rekik, K.
    Marrakchi, C.
    Koubaa, M.
    Ben Jemaa, M.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2022, 128 : S39 - S40
  • [3] Hospitalisation among vaccine breakthrough COVID-19 infections
    Juthani, Prerak, V
    Gupta, Akash
    Borges, Kelly A.
    Price, Christina C.
    Lee, Alfred, I
    Won, Christine H.
    Chun, Hyung J.
    LANCET INFECTIOUS DISEASES, 2021, 21 (11): : 1485 - 1486
  • [4] Age-Related Morbidity and Mortality among Patients with COVID-19
    Kang, Seung-Ji
    Jung, Sook In
    INFECTION AND CHEMOTHERAPY, 2020, 52 (02): : 154 - 164
  • [5] COVID-19 vaccination and breakthrough infections in patients with cancer
    Schmidt, A. L.
    Labaki, C.
    Hsu, C-Y
    Bakouny, Z.
    Balanchivadze, N.
    Berg, S. A.
    Blau, S.
    Daher, A.
    El Zarif, T.
    Friese, C. R.
    Griffiths, E. A.
    Hawley, J. E.
    Hayes-Lattin, B.
    Karivedu, V
    Latif, T.
    Mavromatis, B. H.
    McKay, R. R.
    Nagaraj, G.
    Nguyen, R. H.
    Panagiotou, O. A.
    Portuguese, A. J.
    Puc, M.
    Dutra, M. Santos
    Schroeder, B. A.
    Thakkar, A.
    Wulff-Burchfield, E. M.
    Mishra, S.
    Farmakiotis, D.
    Shyr, Yu
    Warner, J. L.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2022, 33 (03) : 340 - 346
  • [7] Predictors & Mortality Among ≥65 Infected with COVID-19
    Verma, M.
    Stepanova, M.
    Mohess, D.
    Roche-Green, A.
    Mercado, F. Rivera
    Haranis, M.
    Gerber, L.
    Younossi, Z.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 70 : S200 - S201
  • [8] COVID-19 vaccine breakthrough infections
    Gupta, Ravindra K.
    Topol, Eric J.
    SCIENCE, 2021, 374 (6575) : 1561 - 1562
  • [9] Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older
    Wong, Hui-Lee
    Tworkoski, Ellen
    Zhou, Cindy Ke
    Hu, Mao
    Thompson, Deborah
    Lufkin, Bradley
    Do, Rose
    Feinberg, Laurie
    Chillarige, Yoganand
    Dimova, Rositsa
    Lloyd, Patricia C.
    MaCurdy, Thomas
    Forshee, Richard A.
    Kelman, Jeffrey A.
    Shoaibi, Azadeh
    Anderson, Steven A.
    VACCINE, 2023, 41 (02) : 532 - 539
  • [10] Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
    Chien, Kelly S.
    Peterson, Christine B.
    Young, Elliana
    Chihara, Dai
    Manasanch, Elizabet E.
    Ramdial, Jeremy L.
    Thompson, Philip A.
    BLOOD ADVANCES, 2023, 7 (19) : 5691 - 5697